Methods for determining cost-benefit ratios for pharmaceuticals in Germany

Schulenburg J-MG v. d., Vauth C, Mittendorf T, Greiner W (2007)
EUROPEAN JOURNAL OF HEALTH ECONOMICS 8(S1): 5-31.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ;
Abstract / Bemerkung
The aim of this methodological paper is to summarize evidence on how to implement cost-benefit assessment according to the new German legislative framework (Competition Enhancement Act). Given the complexity of existing health policy frameworks within industrialised countries in adapting health economics in their respective regulatory scheme, no clear international scientific consensus on which health economic methods should be chosen for assessment can be determined. Nevertheless, a broad consensus on the internal properties of methods itself can be found. Based on these common international standards in methodology, this work provides a minimum catalogue of methods and criteria that meet legal and local German requirements with regard to specific factors of its health care system. Aside from categorising clearly defined standards (e.g., study forms, cost and benefit categories) the suggested catalogue specifies some intensively debated areas in Germany (e.g., the QALY, modelling, the perspective used in the assessment). After the proposition of certain methods the paper leads to a first recommendation of a detailed assessment-process itself specific for the German way in implementing cost-benefit ratios within regulatory decision making in Germany.
Erscheinungsjahr
Zeitschriftentitel
EUROPEAN JOURNAL OF HEALTH ECONOMICS
Band
8
Ausgabe
S1
Seite(n)
5-31
ISSN
eISSN
PUB-ID

Zitieren

Schulenburg J-MG v. d., Vauth C, Mittendorf T, Greiner W. Methods for determining cost-benefit ratios for pharmaceuticals in Germany. EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2007;8(S1):5-31.
Schulenburg, J. - M. G. v. d., Vauth, C., Mittendorf, T., & Greiner, W. (2007). Methods for determining cost-benefit ratios for pharmaceuticals in Germany. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 8(S1), 5-31. doi:10.1007/s10198-007-0063-4
Schulenburg, J. - M. G. v. d., Vauth, C., Mittendorf, T., and Greiner, W. (2007). Methods for determining cost-benefit ratios for pharmaceuticals in Germany. EUROPEAN JOURNAL OF HEALTH ECONOMICS 8, 5-31.
Schulenburg, J.-M.G. v. d., et al., 2007. Methods for determining cost-benefit ratios for pharmaceuticals in Germany. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 8(S1), p 5-31.
J.-M.G. v. d. Schulenburg, et al., “Methods for determining cost-benefit ratios for pharmaceuticals in Germany”, EUROPEAN JOURNAL OF HEALTH ECONOMICS, vol. 8, 2007, pp. 5-31.
Schulenburg, J.-M.G. v. d., Vauth, C., Mittendorf, T., Greiner, W.: Methods for determining cost-benefit ratios for pharmaceuticals in Germany. EUROPEAN JOURNAL OF HEALTH ECONOMICS. 8, 5-31 (2007).
Schulenburg, J. -Matthias Graf v. d., Vauth, Christoph, Mittendorf, Thomas, and Greiner, Wolfgang. “Methods for determining cost-benefit ratios for pharmaceuticals in Germany”. EUROPEAN JOURNAL OF HEALTH ECONOMICS 8.S1 (2007): 5-31.

6 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Health technology assessment: research trends and future priorities in Europe.
Nielsen CP, Funch TM, Kristensen FB., J Health Serv Res Policy 16 Suppl 2(), 2011
PMID: 21737525
Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.
Stafinski T, Menon D, Davis C, McCabe C., Clinicoecon Outcomes Res 3(), 2011
PMID: 22046102
[Modeling in value-based medicine].
Neubauer AS, Hirneiss C, Kampik A., Ophthalmologe 107(3), 2010
PMID: 20195613
Methods of economic evaluation for the German statutory healthcare system.
Mittendorf T, Greiner W, von der Schulenburg JM., Pharmacoeconomics 27(3), 2009
PMID: 19354346

70 References

Daten bereitgestellt von Europe PubMed Central.


Akehurst, Pharmacoeconomics 17(), 2000
Cost-of-illness studies : a review of current methods.
Akobundu E, Ju J, Blatt L, Mullins CD., Pharmacoeconomics 24(9), 2006
PMID: 16942122
Disability-adjusted life years: a critical review.
Anand S, Hanson K., J Health Econ 16(6), 1997
PMID: 10176779
Opening the debate on DALYs (disability-adjusted life years).
Barker C, Green A., Health Policy Plan 11(2), 1996
PMID: 10172660
Modelling in the economic evaluation of health care: selecting the appropriate approach.
Barton P, Bryan S, Robinson S., J Health Serv Res Policy 9(2), 2004
PMID: 15099459
An introduction to Markov modelling for economic evaluation.
Briggs A, Sculpher M., Pharmacoeconomics 13(4), 1998
PMID: 10178664
The use of probabilistic decision models in technology assessment : the case of total hip replacement.
Briggs A, Sculpher M, Dawson J, Fitzpatrick R, Murray D, Malchau H., Appl Health Econ Health Policy 3(2), 2004
PMID: 15702945
Statistical approaches to handling uncertainty in health economic evaluation.
Briggs AH., Eur J Gastroenterol Hepatol 16(6), 2004
PMID: 15167156
The death of cost-minimization analysis?
Briggs AH, O'Brien BJ., Health Econ 10(2), 2001
PMID: 11252048

AUTHOR UNKNOWN, 0
The friction-cost method : replacement for nothing and leisure for free?
Brouwer WB, Koopmanschap MA., Pharmacoeconomics 23(2), 2005
PMID: 15748085
Need for differential discounting of costs and health effects in cost effectiveness analyses.
Brouwer WB, Niessen LW, Postma MJ, Rutten FF., BMJ 331(7514), 2005
PMID: 16110075

AUTHOR UNKNOWN, 0
A dollar is a dollar is a dollar--or is it?
Brouwer WB, van Exel NJ, Baltussen RM, Rutten FF., Value Health 9(5), 2006
PMID: 16961552
Modelling in economic evaluation: an unavoidable fact of life.
Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, Vray M., Health Econ 6(3), 1997
PMID: 9226140
Economic note: cost of illness studies.
Byford S, Torgerson DJ, Raftery J., BMJ 320(7245), 2000
PMID: 10807635
Pharmacoeconomic analyses using discrete event simulation.
Caro JJ., Pharmacoeconomics 23(4), 2005
PMID: 15853433

AUTHOR UNKNOWN, 0
Interdisciplinary epidemiologic and economic research needed to support a universal childhood influenza vaccination policy.
Coleman MS, Washington ML, Orenstein WA, Gazmararian JA, Prill MM., Epidemiol Rev 28(), 2006
PMID: 16740584

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Health economic guidelines--similarities, differences and some implications.
Hjelmgren J, Berggren F, Andersson F., Value Health 4(3), 2001
PMID: 11705185

Hoffmann, Eur. J. Health Econ. 1(), 2000
The measurement of indirect costs in the health economics evaluation literature. A review.
Jacobs P, Fassbender K., Int J Technol Assess Health Care 14(4), 1998
PMID: 9885468
Assessing the costs of healthcare technologies in clinical trials.
Johnston K, Buxton MJ, Jones DR, Fitzpatrick R., Health Technol Assess 3(6), 1999
PMID: 10350450
Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb.
Jonsson B, Weinstein MC., Int J Technol Assess Health Care 13(1), 1997
PMID: 9119623
The decision rules of cost-effectiveness analysis.
Karlsson G, Johannesson M., Pharmacoeconomics 9(2), 1996
PMID: 10160090

Kobelt, Gesund. Ökon. Qual. Manag. 10(), 2005
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, Strand V, Conaghan PG, Ostergaard M, Maksymowych WP, Landewe R, Bresnihan B, Tak PP, Wakefield R, Mease P, Bingham CO 3rd, Hughes M, Altman D, Buyse M, Galbraith S, Wells G., J. Rheumatol. 34(3), 2007
PMID: 17343307
Burden of illness.
McGuire T, Wells KB, Bruce ML, Miranda J, Scheffler R, Durham M, Ford DE, Lewis L; NIMH Affective Disorders Workgroup., Ment Health Serv Res 4(4), 2002
PMID: 12558002
Understanding DALYs (disability-adjusted life years).
Murray CJ, Acharya AK., J Health Econ 16(6), 1997
PMID: 10176780

AUTHOR UNKNOWN, 0
[Quality adjustment of life years--possibilities, limitations, alternatives]
Nord E., Tidsskr. Nor. Laegeforen. 112(20), 1992
PMID: 1412294

AUTHOR UNKNOWN, 0
Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review.
Rasanen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynanen OP, Roine R., Int J Technol Assess Health Care 22(2), 2006
PMID: 16571199

Ravens-Sieberer, 2000

Rohrbacher, Gesund. Ökon. Qual. Manag. 10(), 2005

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Whither trial-based economic evaluation for health care decision making?
Sculpher MJ, Claxton K, Drummond M, McCabe C., Health Econ 15(7), 2006
PMID: 16491461

AUTHOR UNKNOWN, 0

Tarn, ISPOR Connections 10(), 2004
Developing guidance for budget impact analysis.
Trueman P, Drummond M, Hutton J., Pharmacoeconomics 19(6), 2001
PMID: 11456210

US, Health Qual. Life Outcomes 4(), 2006
Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.
Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR; ISPOR Task Force on Good Research Practices--Modeling Studies., Value Health 6(1), 2003
PMID: 12535234

Zentner, GMS Health Technol. Assess. Doc. 09(), 2005

Zentner, Gesundh. Ökon. Qual. Manag. 11(), 2006

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 17582539
PubMed | Europe PMC

Suchen in

Google Scholar